A detailed history of Wells Fargo & Company transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 43,055 shares of PCVX stock, worth $3.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,055
Previous 35,813 20.22%
Holding current value
$3.62 Million
Previous $2.25 Million 30.77%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$59.79 - $81.05 $432,999 - $586,964
7,242 Added 20.22%
43,055 $2.94 Million
Q4 2023

Feb 09, 2024

SELL
$45.35 - $63.41 $1.12 Million - $1.56 Million
-24,595 Reduced 40.71%
35,813 $2.25 Million
Q3 2023

Nov 13, 2023

SELL
$46.0 - $53.1 $817,972 - $944,224
-17,782 Reduced 22.74%
60,408 $3.08 Million
Q2 2023

Aug 15, 2023

BUY
$34.66 - $54.07 $911,003 - $1.42 Million
26,284 Added 50.64%
78,190 $3.9 Million
Q1 2023

May 12, 2023

BUY
$36.27 - $47.2 $1.74 Million - $2.26 Million
47,945 Added 1210.43%
51,906 $1.95 Million
Q4 2022

Feb 13, 2023

BUY
$20.58 - $47.95 $50,462 - $117,573
2,452 Added 162.49%
3,961 $189,000
Q3 2022

Nov 14, 2022

SELL
$21.69 - $28.53 $8,177 - $10,755
-377 Reduced 19.99%
1,509 $36,000
Q2 2022

Aug 12, 2022

SELL
$17.68 - $26.58 $36,473 - $54,834
-2,063 Reduced 52.24%
1,886 $41,000
Q1 2022

May 16, 2022

SELL
$17.46 - $26.36 $242,868 - $366,667
-13,910 Reduced 77.89%
3,949 $95,000
Q4 2021

Feb 14, 2022

BUY
$19.32 - $26.45 $339,568 - $464,885
17,576 Added 6210.6%
17,859 $425,000
Q3 2021

Nov 15, 2021

SELL
$20.26 - $26.97 $2,532 - $3,371
-125 Reduced 30.64%
283 $7,000
Q2 2021

Aug 16, 2021

SELL
$16.45 - $24.06 $556,733 - $814,286
-33,844 Reduced 98.81%
408 $9,000
Q1 2021

May 13, 2021

SELL
$18.66 - $29.16 $27,411 - $42,836
-1,469 Reduced 4.11%
34,252 $676,000
Q4 2020

Feb 09, 2021

BUY
$26.57 - $51.74 $582,520 - $1.13 Million
21,924 Added 158.9%
35,721 $949,000
Q3 2020

Nov 05, 2020

BUY
$26.5 - $55.4 $365,620 - $764,353
13,797 New
13,797 $681,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $4.99B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.